Black Friday Sale - Ends Soon!
-35% Off Everything
Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$253.1(0.3%)
Market Cap$36.0B
ALNY overview
Crunching data... Almost there!
1W 3.3%
1M (11.1%)
6M 72.2%
YTD 29.8%
1Y 54.3%
3Y 40.0%
5Y 116.0%
10Y 151.3%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
ALNY key stats
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!
ALNY Intrinsic value
ALNY Intrinsic value overview
ALNY Historical intrinsic value
ALNY Financials
ALNY Income statement
Crunching data... Almost there!
ALNY Balance sheet
Crunching data... Almost there!
ALNY Cash flow statement
Crunching data... Almost there!
ALNY Financial ratios
ALNY Growth
Crunching data... Almost there!
ALNY Returns on capital
Crunching data... Almost there!
Compare with peers: operational metrics
Growth & profitability
Solvency & returns
Crunching data... Almost there!
Wall Street estimates
Price target
Crunching data... Almost there!
Crunching data... Almost there!
EPS Surprises
Crunching data... Almost there!
Looking for the most undervalued companies?
Here's our top picks.
Crunching data... Almost there!
Discover more ALNY fundamentals
Stock picking tips.
Ultimate guide 2024
Discover the secrets to successful stock picking in 2024!
We asked 1,000 top investors for their insights on the best stocks, investment strategies, and market trends.
FAQ
What is the Intrinsic Value of Alnylam Pharmaceuticals, Inc. (ALNY) stock?
As of today, intrinsic value of Alnylam Pharmaceuticals, Inc. is $102.1.
Is Alnylam Pharmaceuticals, Inc. (ALNY) stock undervalued or overvalued?
As of today, Alnylam Pharmaceuticals, Inc. is overvalued by 59.7%, compared to the current market share price of $253.1.
What is Alnylam Pharmaceuticals, Inc. (ALNY) stock rating?
As of today, Alnylam Pharmaceuticals, Inc. has a stock rating of 4 (out of 10), which is considered Good.
is Alnylam Pharmaceuticals, Inc. (ALNY) a good stock to buy?
As of today, Alnylam Pharmaceuticals, Inc. has a Good stock rating, which is 59.7% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.